Ustekinumab successfully treated a patient with severe psoriasis vulgaris with primary failure to infliximab and secondary failure to adalimumab

Ustekinumab successfully treated a patient with severe psoriasis vulgaris with primary failure to infliximab and secondary failure to adalimumab

Biologic drugs have been recently used to treat psoriasis. However, some patients do not respond or lose therapeutic benefit with first-line use of tumor necrosis factor (TNF) antagonists. We report a case of psoriasis vulgaris, that failed to respond to TNF antagonists, infliximab and adalimumab, c...

Full description

Bibliographic Details
Main Authors:	Chiharu Tateishi, Hisayoshi Imanishi, Kulsupa Nimmannitya, Daisuke Tsuruta
Format:	Article
Language:	English
Published:	Our Dermatology Online 2015-07-01
Series:	Nasza Dermatologia Online
Subjects:	Ustekinumab; psoriasis; psoriasis vulgaris; infliximab; adalimumab
Online Access:	http://www.odermatol.com/issue-in-html/2015-3-10/

Similar Items

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
by: Matsumoto S, et al.
Published: (2018-07-01)

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial
by: Selma Atalay, et al.
Published: (2022-07-01)

Systemic Psoriasis Treatment at an Early Age (Part II): Issues of Biological Therapy
by: L. S. Namazova-Baranova, et al.
Published: (2018-02-01)

Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors
by: Nicole L. Bolick, et al.
Published: (2020-12-01)

Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience
by: Melis Gönülal, et al.
Published: (2023-12-01)

Tratamiento biológico en psoriasis: Revisión bibliográfica Biologic therapy of psoriasis: Literature review
by: MS Lorenzetti, et al.
Published: (2012-06-01)

Deferred time of delivery of biologic therapies in patients with stabilized psoriasis leads to a ‘perceived satisfaction’: a multicentric study
by: Ambra Di Altobrando, et al.
Published: (2022-01-01)

A retrospective observational study on biological drug treatment in a daily practice serving patients with psoriasis in Japan
by: Chika Ohata, et al.
Published: (2019-01-01)

Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry
by: Abby S. Van Voorhees, et al.
Published: (2021-11-01)

Unilateral Verrucous Psoriasis Successfully Treated With Adalimumab
by: Artur Antônio Duarte, et al.
Published: (2024-01-01)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
by: Norman Wasel, et al.
Published: (2020-05-01)

The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients
by: Michael Abrouk, et al.
Published: (2017-08-01)

Ustekinumab en psoriasis cutánea y artritis psoriásica
by: Javier E. Rosa, et al.
Published: (2015-06-01)

A Case of Severe Panuveitis Associated with Psoriasis Vulgaris Successfully Treated with Infliximab
by: Yuri Sakurai, et al.
Published: (2016-04-01)

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
by: Grace C. Brummer, BS, et al.
Published: (2017-09-01)

Diffuse large B-cell lymphoma that develops after adalimumab using adalimumab in a patient with psoriasis
by: Esra Yıldırım Bay, et al.
Published: (2021-06-01)

Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis
by: Ahmed I. Mourad, et al.
Published: (2021-03-01)

Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab
by: Amy J. Petty, BS, et al.
Published: (2020-08-01)

Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders
by: I. V. Rychkova, et al.
Published: (2019-08-01)

Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab
by: Jeanette Halskou Hesselvig, et al.
Published: (2017-12-01)

Difficulties in choosing a biologic disease-modifying anti-rheumatic drug for the treatment of psoriasis and psoriatic arthritis
by: I. M. Marusenko, et al.
Published: (2019-03-01)

Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
by: Ting-Shun Wang, et al.
Published: (2017-03-01)

Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps)
by: Ayman Elgendi, et al.
Published: (2015-01-01)

PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis
by: Carlo Giovanni Carrera, et al.
Published: (2018-07-01)

Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy
by: Lun-Fei Liu, et al.
Published: (2019-04-01)

Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
by: Savas Yayli, et al.
Published: (2013-11-01)

Targeting psoriasis with new therapies
by: A.Prohić;H. Helppikangas;J. Muhović
Published: (2007-08-01)

Paradoxical Psoriasis Induced by Ustekinumab: A Comprehensive Review and Case Report
by: Artsiom Klimko, et al.
Published: (2024-01-01)

Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis
by: Rosa M. Romero-Jimenez, et al.
Published: (2018-11-01)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
by: Jerry Bagel, et al.
Published: (2018-10-01)

Effectiveness of resuming ustekinumab therapy in psoriasis patients with metabolic disorders. Clinical experience
by: I. V. Rychkova, et al.
Published: (2019-02-01)

Efficacy and safety of ustekinumab in adolescents
by: Kellen R, et al.
Published: (2016-09-01)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
by: Subedi S, et al.
Published: (2019-07-01)

Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
by: Tatyana Valentinovna Mezenova, et al.
Published: (2012-04-01)

Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases
by: Rosita Saraceno, et al.
Published: (2013-09-01)

The use of ustekinumab in patients with psoriasis and coexisting renal or hepatic dysfunction – a report of two cases
by: Hubert Arasiewicz, et al.
Published: (2014-10-01)

A case report of heart failure after therapy with ustekinumab
by: Kourosh Beroukhim, et al.
Published: (2015-07-01)

Hypophysitis following Treatment with Ustekinumab: Radiological and Pathological Findings
by: Ana M. Ramos-Leví, et al.
Published: (2018-03-01)

Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis
by: Misbah N. Ghazanfar, et al.
Published: (2019-07-01)

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis
by: Zhanhan TANG, et al.
Published: (2023-04-01)